Axsome Therapeutics (NASDAQ:AXSM) COO Sells $5,726,990.64 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark Jacobson sold 35,378 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $161.88, for a total transaction of $5,726,990.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Axsome Therapeutics Stock Up 0.4%

Shares of AXSM opened at $163.89 on Monday. The business’s fifty day moving average price is $175.78 and its two-hundred day moving average price is $146.61. The firm has a market capitalization of $8.38 billion, a price-to-earnings ratio of -44.41 and a beta of 0.43. Axsome Therapeutics, Inc. has a 52 week low of $86.99 and a 52 week high of $191.50. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.48 and a current ratio of 1.55.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.14. The business had revenue of $196.00 million for the quarter, compared to analyst estimates of $191.33 million. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The business’s revenue for the quarter was up 65.0% compared to the same quarter last year. On average, analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics News Summary

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
• Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
• Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on AXSM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 21st. Truist Financial set a $200.00 target price on shares of Axsome Therapeutics in a report on Monday, February 23rd. Robert W. Baird set a $209.00 price target on Axsome Therapeutics in a research note on Tuesday, January 13th. Needham & Company LLC restated a “buy” rating and issued a $225.00 price target on shares of Axsome Therapeutics in a research report on Monday, February 23rd. Finally, Wells Fargo & Company upped their price objective on Axsome Therapeutics from $193.00 to $202.00 and gave the company an “overweight” rating in a report on Tuesday, February 24th. Seventeen equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.12.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Versant Capital Management Inc grew its holdings in Axsome Therapeutics by 20,300.0% in the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after buying an additional 203 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of Axsome Therapeutics in the fourth quarter valued at about $31,000. First Horizon Corp acquired a new position in shares of Axsome Therapeutics in the third quarter valued at about $34,000. Optiver Holding B.V. increased its position in Axsome Therapeutics by 82.3% during the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after acquiring an additional 130 shares during the period. Finally, Ameriflex Group Inc. acquired a new stake in Axsome Therapeutics in the 4th quarter worth about $37,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.